Loading...
XSWX
ALC
Market cap46bUSD
Apr 01, Last price  
82.32CHF
1D
-1.08%
1Q
7.05%
IPO
42.82%
Name

Alcon AG

Chart & Performance

D1W1MN
No data to show
P/E
45.26
P/S
4.65
EPS
2.06
Div Yield, %
0.58%
Shrs. gr., 5y
0.38%
Rev. gr., 5y
5.71%
Revenues
9.91b
+4.82%
6,517,955,3426,596,000,0006,792,000,0007,153,000,0007,508,000,0006,833,000,0008,291,000,0008,717,000,0009,455,000,0009,911,000,000
Net income
1.02b
+4.52%
296,270,697-170,000,000256,000,000-227,000,000-656,000,000-531,000,000376,000,000335,000,000974,000,0001,018,000,000
CFO
2.08b
+40.20%
1,317,827,4521,245,000,0001,218,000,0001,140,000,000920,000,000823,000,0001,345,000,0001,217,000,0001,481,502,1072,077,000,000
Dividend
May 14, 20240.24 CHF/sh
Earnings
May 08, 2025

Profile

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
URL
https://www.alcon.ch/
IPO date
Apr 09, 2019
Employees
25,000
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,911,000
4.82%
9,455,000
8.47%
8,717,000
5.14%
Cost of revenue
5,275,000
5,067,000
4,671,000
Unusual Expense (Income)
NOPBT
4,636,000
4,388,000
4,046,000
NOPBT Margin
46.78%
46.41%
46.42%
Operating Taxes
238,000
(142,000)
128,000
Tax Rate
5.13%
3.16%
NOPAT
4,398,000
4,530,000
3,918,000
Net income
1,018,000
4.52%
974,000
190.75%
335,000
-10.90%
Dividends
(130,000)
(116,000)
(103,281)
Dividend yield
0.34%
0.36%
0.33%
Proceeds from repurchase of equity
(49,000)
(50,000)
BB yield
0.15%
0.16%
Debt
Debt current
169,000
216,000
168,000
Long-term debt
5,464,000
5,335,000
5,330,000
Deferred revenue
86,000
556,000
Other long-term liabilities
739,000
784,000
230,000
Net debt
3,052,000
4,131,000
4,410,000
Cash flow
Cash from operating activities
2,077,000
1,481,502
1,217,000
CAPEX
(473,000)
(660,000)
(745,000)
Cash from investing activities
(1,167,000)
(1,094,000)
(1,865,000)
Cash from financing activities
(322,000)
(211,000)
(8,000)
FCF
4,146,086
3,425,914
3,496,000
Balance
Cash
1,830,000
1,101,000
980,000
Long term investments
751,000
319,000
108,000
Excess cash
2,085,450
947,250
652,150
Stockholders' equity
21,553,000
20,617,016
19,677,000
Invested Capital
25,428,550
25,606,590
24,561,850
ROIC
17.24%
18.06%
16.41%
ROCE
16.42%
16.04%
15.40%
EV
Common stock shares outstanding
497,500
496,500
494,400
Price
76.90
17.15%
65.64
3.89%
63.18
-21.75%
Market cap
38,257,750
17.39%
32,590,260
4.33%
31,236,192
-21.59%
EV
41,309,750
36,721,260
35,646,192
EBITDA
5,864,000
5,691,252
5,169,000
EV/EBITDA
7.04
6.45
6.90
Interest
192,000
189,000
134,000
Interest/NOPBT
4.14%
4.31%
3.31%